Chapter/Section Purchase

1 Hemophilia A Drug Market Overview
1.1 Product Overview and Scope of Hemophilia A Drug
1.2 Hemophilia A Drug Segment by Type
1.2.1 Global Hemophilia A Drug Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 ATXF-8117
1.2.3 BAY-1093884
1.2.4 BIVV-001
1.2.5 BS-027125
1.2.6 Concizumab
1.2.7 CSL-689
1.2.8 Others
1.3 Hemophilia A Drug Segment by Application
1.3.1 Global Hemophilia A Drug Sales Comparison by Application: (2022-2028)
1.3.2 Clinic
1.3.3 Hospital
1.3.4 ASCs
1.4 Global Hemophilia A Drug Market Size Estimates and Forecasts
1.4.1 Global Hemophilia A Drug Revenue 2017-2028
1.4.2 Global Hemophilia A Drug Sales 2017-2028
1.4.3 Hemophilia A Drug Market Size by Region: 2017 Versus 2021 Versus 2028
2 Hemophilia A Drug Market Competition by Manufacturers
2.1 Global Hemophilia A Drug Sales Market Share by Manufacturers (2017-2022)
2.2 Global Hemophilia A Drug Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Hemophilia A Drug Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Hemophilia A Drug Manufacturing Sites, Area Served, Product Type
2.5 Hemophilia A Drug Market Competitive Situation and Trends
2.5.1 Hemophilia A Drug Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Hemophilia A Drug Players Market Share by Revenue
2.5.3 Global Hemophilia A Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Hemophilia A Drug Retrospective Market Scenario by Region
3.1 Global Hemophilia A Drug Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Hemophilia A Drug Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Hemophilia A Drug Market Facts & Figures by Country
3.3.1 North America Hemophilia A Drug Sales by Country
3.3.2 North America Hemophilia A Drug Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Hemophilia A Drug Market Facts & Figures by Country
3.4.1 Europe Hemophilia A Drug Sales by Country
3.4.2 Europe Hemophilia A Drug Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Hemophilia A Drug Market Facts & Figures by Region
3.5.1 Asia Pacific Hemophilia A Drug Sales by Region
3.5.2 Asia Pacific Hemophilia A Drug Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Hemophilia A Drug Market Facts & Figures by Country
3.6.1 Latin America Hemophilia A Drug Sales by Country
3.6.2 Latin America Hemophilia A Drug Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Hemophilia A Drug Market Facts & Figures by Country
3.7.1 Middle East and Africa Hemophilia A Drug Sales by Country
3.7.2 Middle East and Africa Hemophilia A Drug Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Hemophilia A Drug Historic Market Analysis by Type
4.1 Global Hemophilia A Drug Sales Market Share by Type (2017-2022)
4.2 Global Hemophilia A Drug Revenue Market Share by Type (2017-2022)
4.3 Global Hemophilia A Drug Price by Type (2017-2022)
5 Global Hemophilia A Drug Historic Market Analysis by Application
5.1 Global Hemophilia A Drug Sales Market Share by Application (2017-2022)
5.2 Global Hemophilia A Drug Revenue Market Share by Application (2017-2022)
5.3 Global Hemophilia A Drug Price by Application (2017-2022)
6 Key Companies Profiled
6.1 Bayer AG
6.1.1 Bayer AG Corporation Information
6.1.2 Bayer AG Description and Business Overview
6.1.3 Bayer AG Hemophilia A Drug Sales, Revenue and Gross Margin (2017-2022)
6.1.4 Bayer AG Hemophilia A Drug Product Portfolio
6.1.5 Bayer AG Recent Developments/Updates
6.2 BioMarin Pharmaceutical Inc
6.2.1 BioMarin Pharmaceutical Inc Corporation Information
6.2.2 BioMarin Pharmaceutical Inc Description and Business Overview
6.2.3 BioMarin Pharmaceutical Inc Hemophilia A Drug Sales, Revenue and Gross Margin (2017-2022)
6.2.4 BioMarin Pharmaceutical Inc Hemophilia A Drug Product Portfolio
6.2.5 BioMarin Pharmaceutical Inc Recent Developments/Updates
6.3 Bioverativ Inc
6.3.1 Bioverativ Inc Corporation Information
6.3.2 Bioverativ Inc Description and Business Overview
6.3.3 Bioverativ Inc Hemophilia A Drug Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Bioverativ Inc Hemophilia A Drug Product Portfolio
6.3.5 Bioverativ Inc Recent Developments/Updates
6.4 Catalyst Biosciences Inc
6.4.1 Catalyst Biosciences Inc Corporation Information
6.4.2 Catalyst Biosciences Inc Description and Business Overview
6.4.3 Catalyst Biosciences Inc Hemophilia A Drug Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Catalyst Biosciences Inc Hemophilia A Drug Product Portfolio
6.4.5 Catalyst Biosciences Inc Recent Developments/Updates
6.5 Chugai Pharmaceutical Co Ltd
6.5.1 Chugai Pharmaceutical Co Ltd Corporation Information
6.5.2 Chugai Pharmaceutical Co Ltd Description and Business Overview
6.5.3 Chugai Pharmaceutical Co Ltd Hemophilia A Drug Sales, Revenue and Gross Margin (2017-2022)
6.5.4 Chugai Pharmaceutical Co Ltd Hemophilia A Drug Product Portfolio
6.5.5 Chugai Pharmaceutical Co Ltd Recent Developments/Updates
6.6 CSL Ltd
6.6.1 CSL Ltd Corporation Information
6.6.2 CSL Ltd Description and Business Overview
6.6.3 CSL Ltd Hemophilia A Drug Sales, Revenue and Gross Margin (2017-2022)
6.6.4 CSL Ltd Hemophilia A Drug Product Portfolio
6.6.5 CSL Ltd Recent Developments/Updates
6.7 DBV Technologies SA
6.6.1 DBV Technologies SA Corporation Information
6.6.2 DBV Technologies SA Description and Business Overview
6.6.3 DBV Technologies SA Hemophilia A Drug Sales, Revenue and Gross Margin (2017-2022)
6.4.4 DBV Technologies SA Hemophilia A Drug Product Portfolio
6.7.5 DBV Technologies SA Recent Developments/Updates
6.8 Dimension Therapeutics Inc
6.8.1 Dimension Therapeutics Inc Corporation Information
6.8.2 Dimension Therapeutics Inc Description and Business Overview
6.8.3 Dimension Therapeutics Inc Hemophilia A Drug Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Dimension Therapeutics Inc Hemophilia A Drug Product Portfolio
6.8.5 Dimension Therapeutics Inc Recent Developments/Updates
6.9 EpiVax Inc
6.9.1 EpiVax Inc Corporation Information
6.9.2 EpiVax Inc Description and Business Overview
6.9.3 EpiVax Inc Hemophilia A Drug Sales, Revenue and Gross Margin (2017-2022)
6.9.4 EpiVax Inc Hemophilia A Drug Product Portfolio
6.9.5 EpiVax Inc Recent Developments/Updates
6.10 Expression Therapeutics LLC
6.10.1 Expression Therapeutics LLC Corporation Information
6.10.2 Expression Therapeutics LLC Description and Business Overview
6.10.3 Expression Therapeutics LLC Hemophilia A Drug Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Expression Therapeutics LLC Hemophilia A Drug Product Portfolio
6.10.5 Expression Therapeutics LLC Recent Developments/Updates
6.11 Green Cross Corp
6.11.1 Green Cross Corp Corporation Information
6.11.2 Green Cross Corp Hemophilia A Drug Description and Business Overview
6.11.3 Green Cross Corp Hemophilia A Drug Sales, Revenue and Gross Margin (2017-2022)
6.11.4 Green Cross Corp Hemophilia A Drug Product Portfolio
6.11.5 Green Cross Corp Recent Developments/Updates
6.12 Idogen AB
6.12.1 Idogen AB Corporation Information
6.12.2 Idogen AB Hemophilia A Drug Description and Business Overview
6.12.3 Idogen AB Hemophilia A Drug Sales, Revenue and Gross Margin (2017-2022)
6.12.4 Idogen AB Hemophilia A Drug Product Portfolio
6.12.5 Idogen AB Recent Developments/Updates
6.13 Immusoft Corp
6.13.1 Immusoft Corp Corporation Information
6.13.2 Immusoft Corp Hemophilia A Drug Description and Business Overview
6.13.3 Immusoft Corp Hemophilia A Drug Sales, Revenue and Gross Margin (2017-2022)
6.13.4 Immusoft Corp Hemophilia A Drug Product Portfolio
6.13.5 Immusoft Corp Recent Developments/Updates
6.14 LFB SA
6.14.1 LFB SA Corporation Information
6.14.2 LFB SA Hemophilia A Drug Description and Business Overview
6.14.3 LFB SA Hemophilia A Drug Sales, Revenue and Gross Margin (2017-2022)
6.14.4 LFB SA Hemophilia A Drug Product Portfolio
6.14.5 LFB SA Recent Developments/Updates
6.15 mAbxience SA
6.15.1 mAbxience SA Corporation Information
6.15.2 mAbxience SA Hemophilia A Drug Description and Business Overview
6.15.3 mAbxience SA Hemophilia A Drug Sales, Revenue and Gross Margin (2017-2022)
6.15.4 mAbxience SA Hemophilia A Drug Product Portfolio
6.15.5 mAbxience SA Recent Developments/Updates
7 Hemophilia A Drug Manufacturing Cost Analysis
7.1 Hemophilia A Drug Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Hemophilia A Drug
7.4 Hemophilia A Drug Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Hemophilia A Drug Distributors List
8.3 Hemophilia A Drug Customers
9 Hemophilia A Drug Market Dynamics
9.1 Hemophilia A Drug Industry Trends
9.2 Hemophilia A Drug Market Drivers
9.3 Hemophilia A Drug Market Challenges
9.4 Hemophilia A Drug Market Restraints
10 Global Market Forecast
10.1 Hemophilia A Drug Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Hemophilia A Drug by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Hemophilia A Drug by Type (2023-2028)
10.2 Hemophilia A Drug Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Hemophilia A Drug by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Hemophilia A Drug by Application (2023-2028)
10.3 Hemophilia A Drug Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Hemophilia A Drug by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Hemophilia A Drug by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer